Dr Jean Abraham
Consultant Medical Oncologist

Dr Jean Abraham graduated from the University of Liverpool Medical School and completed her training in General Medicine and Oncology in Cambridge. Prior to undertaking her medical degree she completed a BSc (Hons) degree in pharmacology, focusing particularly on drug toxicities. She was awarded a National Cancer Research UK Clinical Training Research Fellowship and completed a PhD in Breast Cancer Pharmacogenetics at the University of Cambridge in 2011. Since October 2011 she has been in post as a Consultant Medical Oncologist in Cambridge.

She is co-author of the Anglia Cancer Network Breast Cancer Chemotherapy Treatment Algorithms, which defines the treatment pathways for breast cancer in the neo-adjuvant, adjuvant and metastatic setting for patients within the Anglia cancer network. She has a particular interest in the management and treatment of high risk and hereditary breast cancers. She is actively involved in leading the design and development of biomarker directed clinical trials, which aims to treat patients in a more targeted fashion.

Her current research focus is in cancer pharmacogenetics (the relationship between genetics, drug response and/or drug toxicity). Her work in breast cancer pharmacogenetics investigates the development of biomarkers to predict for toxicity and response for chemotherapy and hormone therapy. She is Chief Investigator of the national pharmacogenetics study PGSNPS and also pharmacogenetics lead on several UK breast cancer studies. She has established research collaborations throughout the UK, USA, Japan and the Netherlands.